MDM Templates
Hemoptysis — Mild/Non-Massive
Patient presents with hemoptysis. Presentation is well-appearing with stable vital signs, adequate oxygenation, and no respiratory distress. Volume is modest (estimated *** mL), and hemodynamic parameters are reassuring. History and exam lower suspicion for massive hemorrhage, airway compromise, and acute decompensation.
Plan: Chest imaging obtained to evaluate for infectious, malignant, and structural etiologies. Patient admitted for observation, serial vital sign assessment, and cross-typed blood. Nothing by mouth pending reassessment. Close monitoring for any increase in bleeding volume or change in hemodynamic status.
Disposition: Admit to floor bed with frequent vitals, strict intake/output, and serial exams. Pulmonology consulted for diagnostic workup. Inform patient of return precautions: any increase in bleeding volume, dyspnea, hemodynamic instability, or chest pain should prompt immediate evaluation. Follow-up CT chest with contrast arranged within 1-2 weeks if not obtained acutely.
Hemoptysis — Massive/Life-Threatening
Patient presents with massive hemoptysis (>600 mL/24 hours or >100 mL/hour, or any volume with hemodynamic instability or airway compromise). Patient is hemodynamically unstable with relative hypoxemia. Presentation is immediately life-threatening — the critical danger is airway obstruction from aspiration and drowning in blood, not hemorrhagic shock.
Airway and positioning: Airway secured emergently. Given the source of bleeding (*** lung), patient positioned with bleeding side down to allow contralateral lung to remain clear and exchange gas. Large endotracheal tube (8.0 or greater) placed to permit bronchial suctioning. If equipment and expertise available, consider selective intubation of non-bleeding lung or placement of bronchial blocker to isolate bleeding source. Immediate rigid bronchoscopy and visualization of bleeding source performed to guide next intervention.
Resuscitation and monitoring: Two large-bore IVs placed. Massive transfusion protocol activated — type O blood released emergently. Goal is restoration of hemoglobin and hemostasis. Continuous cardiopulmonary monitoring. Invasive arterial line placed for real-time blood pressure and arterial blood gas monitoring. Central venous access obtained for volume assessment and medication administration.
Definitive hemostasis: Interventional radiology consulted emergently for bronchial artery embolization — the definitive intervention for massive hemoptysis from bronchial artery sources. Most hemoptysis originates from hyperplastic systemic (bronchial) arteries rather than low-pressure pulmonary circulation; embolization has >90% success rate. Do not delay for any reason. Surgery held in reserve for patients in whom IR intervention fails and those with hemoptysis from massive AVM or pulmonary artery rupture.
Disposition: ICU admission. Admit to ICU immediately for post-embolization monitoring, continued resuscitation, mechanical ventilation weaning, and assessment for re-bleeding.
Diffuse Alveolar Hemorrhage (DAH)
Patient presents with hemoptysis, dyspnea, and anemia. Examination shows bilateral crackles. Chest imaging reveals bilateral alveolar infiltrates. Hemoglobin serially declining (admission *** g/dL, prior *** g/dL). Presentation concerning for diffuse alveolar hemorrhage from autoimmune vasculitis.
History and clinical pattern raise suspicion for underlying ANCA-associated vasculitis (granulomatosis with polyangiitis/GPA, microscopic polyangiitis), anti-glomerular basement membrane disease (Goodpasture syndrome), lupus-associated diffuse alveolar hemorrhage, or other systemic vasculitis. Serologic workup initiated: ANCA panel, anti-GBM, ANA, complement levels, comprehensive metabolic panel with creatinine, urinalysis (assess for hematuria/proteinuria consistent with glomerulonephritis).
If acute respiratory failure present: Mechanical ventilation support provided. Emergent plasmapheresis considered given the rapidly progressive nature of DAH and high mortality if untreated. Rheumatology and pulmonology consulted urgently. Plasma exchange performed to remove circulating autoantibodies — critical for Goodpasture and ANCA vasculitis. Immunosuppression (high-dose corticosteroids, cyclophosphamide per rheumatology guidance) initiated in parallel with plasmapheresis.
Disposition: ICU admission for mechanical ventilation support, plasmapheresis coordination, and close monitoring of renal function and oxygenation. Rheumatology input essential for immunosuppressive regimen and long-term management.
Clinical Education
Definition and Severity Stratification
Hemoptysis is the expectoration of blood from the respiratory tract [1]. Volume classification guides initial management and helps distinguish between those requiring outpatient investigation and those requiring admission and urgent intervention. Mild hemoptysis is typically defined as less than 100 mL over 24 hours, moderate hemoptysis as 100-600 mL over 24 hours, and massive hemoptysis as greater than 600 mL per 24 hours or greater than 100 mL per hour [2]. However, any volume causing respiratory compromise, hemodynamic instability, or airway obstruction is functionally “massive” and demands emergent intervention regardless of absolute volume.
The clinical severity — not the absolute volume — drives management decisions. A patient with 200 mL hemoptysis who is hypoxemic and hemodynamically unstable requires ICU admission and urgent imaging. A patient with 500 mL but who is stable, oxygenating well, and hemodynamically normal may be observed as an inpatient with pulmonology follow-up.
Common Etiologies
Bronchitis is the single most common cause of hemoptysis overall, especially in smokers with acute viral or bacterial infection causing mucosal irritation and mild hemoptysis. Most bronchitis-related hemoptysis is mild and self-limited with expectoration of blood-tinged sputum rather than frank bleeding.
In patients with recurrent or persistent hemoptysis, the differential shifts toward structural and chronic diseases: pulmonary tuberculosis (historically the leading serious cause, remains common globally and in immunocompromised patients), bronchogenic malignancy (bronchogenic carcinoma, especially in smokers), and bronchiectasis (chronic airway destruction leading to recurrent infection and friable vasculature). These diagnoses mandate urgent CT imaging and pulmonology referral.
Pulmonary embolism can present as hemoptysis [3] — the mechanism is pulmonary infarction from wedge-shaped perfusion defect in the context of a baseline risk factor (hypercoagulability, immobility, recent surgery). The classic presentation is pleuritic chest pain, dyspnea, and hemoptysis. Any patient with hemoptysis warrants assessment for DVT risk and PE probability.
In massive hemoptysis, the sources shift toward high-flow vascular sources: bleeding bronchial arteries (systemically hypertensive, prone to aneurysmal dilation and rupture, especially in TB or chronic airway disease), pulmonary artery aneurysm or rupture (Swan-Ganz catheter perforation is a known iatrogenic cause; congenital aneurysms also occur), and massive arteriovenous malformations. These require urgent bronchoscopy and IR evaluation.
Airway Management in Massive Hemoptysis
The critical threat in massive hemoptysis is airway obstruction, not hemorrhagic shock. A patient with 2 liters of blood loss is severely anemic, but a patient with blood filling their airway is immediately dead — asphyxiation occurs faster than exsanguination.
Positioning is the first intervention: place the patient with the bleeding side down (injured lung dependent). This uses gravity to keep blood in the bleeding lung and out of the airway of the contralateral lung, maximizing gas exchange on the non-bleeding side. If the source is unclear, left side down is a reasonable default (left lung has only one lobe and is slightly less critical for gas exchange).
Intubation strategy: The goal is to protect the non-bleeding airway and permit visualization and intervention on the bleeding source. Place a large endotracheal tube (8.0 mm or larger) to allow rigid bronchoscopy and suctioning. If possible, perform selective intubation of the non-bleeding lung — advance the tube past the carina into the non-bleeding mainstem bronchus and inflate the cuff, isolating the bleeding lung and allowing the non-bleeding lung to ventilate and oxygenate [4]. This buys time and improves oxygenation while awaiting IR intervention.
If selective intubation is not feasible, a bronchial blocker can be placed (fogarty catheter, endobronchial blocker, or purpose-built blocker) to occlude the bleeding mainstem bronchus and prevent blood aspiration into the non-bleeding lung. This is a temporizing measure — the definitive intervention is still IR embolization or surgical intervention.
Rigid bronchoscopy performed at the bedside or in the OR permits direct visualization of the bleeding source, allows aggressive suctioning to clear blood and improve visualization, and enables therapeutic interventions (topical hemostatics, epinephrine-soaked gauze packing, or laser/cautery if available and appropriate).
Interventional Radiology and Embolization
Bronchial artery embolization is the definitive intervention for massive hemoptysis from systemic arterial sources and has a success rate exceeding 90% [5]. Most massive hemoptysis originates from hyperplastic bronchial arteries (systemic circulation, pressurized) rather than from the low-pressure pulmonary arterial system. These vessels undergo pathologic dilation and aneurysmal changes, especially in tuberculosis, bronchiectasis, and chronic inflammatory lung disease.
Technique: Interventional radiologists perform angiography to identify the bleeding source (typically an enlargement, dysplasia, or actively extravasating bronchial artery), then deploy embolic material (particles, coils, or liquid embolic agents) to occlude the vessel and stop bleeding. The procedure is performed under fluoroscopy, often with conscious sedation or general anesthesia if the patient is mechanically ventilated.
Timing is critical: do not delay IR consultation in a patient with massive hemoptysis. While rigid bronchoscopy may be performed emergently to secure the airway and visualize the source, the definitive hemostasis comes from embolization. Consult IR immediately — they will communicate with the ICU team regarding timing and coordination of angiography.
Recurrence of hemoptysis after embolization can occur (reported 10-15% at 1 year) due to collateral angiogenesis or recanalization of the embolized vessel. Re-embolization can be performed. However, the initial embolization is highly effective at controlling acute, life-threatening bleeding.
Diffuse Alveolar Hemorrhage and Autoimmune Etiology
Diffuse alveolar hemorrhage (DAH) is a medical emergency characterized by acute bleeding into the alveoli from autoimmune small-vessel vasculitis [6]. The classic presentation is hemoptysis, dyspnea, and acute anemia with bilateral alveolar infiltrates on imaging. The hallmark is a serially declining hemoglobin — the patient is bleeding into the lung in real time.
Key etiologies include ANCA-associated vasculitis (granulomatosis with polyangiitis/GPA, formerly Wegener granulomatosis, and microscopic polyangiitis), anti-glomerular basement membrane disease (Goodpasture syndrome, which often includes concurrent glomerulonephritis causing pulmonary-renal syndrome), systemic lupus erythematosus, and other connective tissue disorders. All carry a mortality rate exceeding 50% if untreated [7].
Urgent workup: ANCA panel (c-ANCA for GPA, p-ANCA for MPA), anti-GBM antibodies, ANA, comprehensive metabolic panel with creatinine (assess for concurrent glomerulonephritis), urinalysis (hematuria, proteinuria, RBC casts are classic for glomerulonephritis). Chest imaging shows bilateral alveolar infiltrates (classically described as “bat wing” pattern, though not pathognomonic).
Plasmapheresis: Emergent plasma exchange is indicated for DAH, especially if accompanied by renal failure or rapidly progressive disease. The mechanism is removal of circulating autoantibodies (anti-ANCA, anti-GBM) and immune complexes, reducing the inflammatory insult to the vasculature. Plasmapheresis is performed in parallel with immunosuppression (high-dose corticosteroids, cyclophosphamide) and buys time for the immunosuppressive medications to take effect. This requires ICU-level coordination with rheumatology and/or pulmonology.
Hemoptysis vs. Hematemesis: Clinical Distinction
Distinguishing hemoptysis (blood from the lungs) from hematemesis (blood from the upper GI tract) is essential because misdiagnosis leads to wrong treatment. Most of the features are clinical rather than laboratory.
| Feature | Hemoptysis | Hematemesis |
|---|---|---|
| Color/appearance | Bright red, frothy, mixed with sputum | Coffee-ground (dark), mixed with food/gastric content |
| pH | Alkaline (pH >7) | Acidic (pH <7) |
| Associated symptoms | Dyspnea, cough, chest discomfort | Nausea, abdominal pain, recent alcohol use or retching |
| Exam findings | Lung findings (crackles, wheezes, focal consolidation) | GI signs (epigastric tenderness, signs of varices or liver disease) |
| History | Respiratory symptoms preceding bleed; lung disease risk factors | GI symptoms; GERD, alcohol use, PUD risk factors |
The clinical history and examination are usually diagnostic. A patient who reports coughing up blood while having a productive cough is having hemoptysis; a patient who vomits blood with retching and abdominal pain is having hematemesis. When in doubt, staining the expectorated blood with a dipstick — a bright pH >7 suggests respiratory origin, while acidic material suggests swallowed gastric content.
Disposition and Follow-Up
Mild hemoptysis (<100 mL/24h) in a hemodynamically stable, well-oxygenating patient without respiratory distress can often be managed as an outpatient with urgent pulmonology referral and CT chest performed within 1-2 weeks. The patient must be reliable for follow-up and have clear return precautions. Patients with any risk factors for malignancy (age >40, significant smoking history, occupational exposures) warrant CT imaging before discharge.
Moderate hemoptysis (100-600 mL/24h) or any hemoptysis with hemodynamic instability, hypoxemia, or respiratory distress requires hospital admission for observation, cross-matched blood availability, serial vital signs, and close monitoring. Pulmonology consultation arranged for diagnostic bronchoscopy or imaging as indicated. Most patients admitted for moderate hemoptysis can be managed on a floor bed (not ICU) unless there is evidence of continued bleeding or decompensation.
Massive hemoptysis requires ICU admission immediately. Massive hemoptysis from anticoagulation (warfarin, DOAC, heparin) warrants closer evaluation and consideration of reversal agents; reversal of anticoagulation alone does not always stop lung bleeding and should be coupled with diagnostic evaluation (bronchoscopy, imaging, IR assessment) to identify and treat the underlying source.
Return precautions for all patients discharged with hemoptysis: Return immediately if hemoptysis volume increases, dyspnea worsens, chest pain develops, syncope occurs, or hemodynamic instability develops. Inform patients that any hemoptysis greater than a few teaspoons warrants reevaluation.
References
- Jean-Baptiste E. Clinical assessment and management of massive hemoptysis. Crit Care Med. 2000;28(5):1642-1647. PubMed
- Hirshberg B, Biran H, Glazer M, Kramer MR. Hemoptysis: etiology, evaluation, and outcome in a tertiary referral center. Chest. 1997;112(2):440-444. PubMed
- Miniati M, Pistolesi M, Imberti D, et al. Hemoptysis: epidemiology, etiology, and outcome in a large series of patients. Eur Respir J. 2015;46(S59):OA4644.
- Cahill BC, Ingbar DH. Massive hemoptysis. Assessment and management. Clin Chest Med. 1994;15(1):147-167. PubMed
- Rémy J, Arnaud A, Fardou H, Giraud R, Voisin C. Treatment of hemoptysis by embolization of bronchial arteries. Radiology. 1981;122(1):33-37. PubMed
- Lara AR, Schwarz MI. Diffuse alveolar hemorrhage. Chest. 2010;137(5):1164-1171. PubMed
- Collard HR, Aguilar GC, Jennings CA, et al. Diffuse alveolar hemorrhage secondary to anti-glomerular basement membrane antibody disease. Am J Respir Crit Care Med. 1996;154(5):1427-1430. PubMed
tydotphrase.com 